




SYNERGY™ XD

Everolimus-Eluting Platinum
Chromium Coronary Stent System



Xtra Deliverability
Optimal Healing

Know you'll get there

SYNERGY™ XD


Everolimus-Eluting Platinum
Chromium Coronary Stent System

Introducing: the next generation SYNERGY™ Bioabsorbable Polymer (BP) Stent. The SYNERGY XD Stent System is equipped with a delivery system designed to make optimal healing even more deliverable.

Innovative Delivery System for
**Deliverability beyond
compare** 

- Increased Pushability*
- Increased Trackability*

* Based on bench testing of SYNERGY and SYNERGY XD BP Stents. Radial Guide Tracking and Radial Push Transmission; 3.00 mm stent systems tested, n=15 units. Bench testing performed by Boston Scientific. Results not necessarily indicative of clinical performance.





Fast Polymer Absorption for **Optimal Healing**

- Proven SYNERGY BP Stent
- Trusted Drug and Abluminal Polymer



Xtra Deliverability


Meaningful innovation of the SYNERGY Delivery System



Increased Trackability
Extended Lubricious Coating*

Increased Pushability
Enhanced Laser-cut
Hypotube Technology*

The **SYNERGY XD™ Stent System** combines added **trackability** and **pushability** with a **low-profile** stent platform to enable better navigation of the subclavian artery in radial PCI cases




**SEE THE
VIDEO**



* Based on bench testing of SYNERGY and SYNERGY XD BP Stents. Radial Guide Tracking and Radial Push Transmission; 3.00 mm stent systems tested, n=15 units. Bench testing performed by Boston Scientific. Results not necessarily indicative of clinical performance.

† Based on the 4.0 - 5.0 mm stent models.






Optimal Healing

Fast Absorbing Bioabsorbable Polymer Advantage


Unlike permanent polymer DES technology, the SYNERGY XD™ Bioabsorbable Polymer is gone shortly after the drug is completely eluted¹

Optimal Everolimus Drug Delivery
Synchronous drug elution &
polymer absorption



Fast Polymer Absorption
The 4-month absorption time
is 6x faster than other BP Stent[‡]

Abluminal Polymer Application
Suppresses neointimal growth
while promoting early healing



Thin, Rounded Struts
Stents with thinner struts heal faster
than thicker stent struts²

‡ Compared to Orsiro BP Stent.

1. Wilson GJ, et al. *Catheter Cardiovasc Interv.*

2. Soucy N, Feygin J et al, *EuroIntervention.* 2010 Nov;6(5):630-7.

Excellent Safety & Long Term Outcomes

The SYNERGY™ BP Stent has been studied in over 35,000 patients across various patient and lesion complexities



ZERO ST

After patients stopped DAPT at
1-month through 12-months
SENIOR Trial³

RANKED #1

Lowest Relative Risk of Def/Prob ST
Kang Network Meta-Analysis⁴



0.2% ST

After Patients stopped DAPT at
3-months through 15-months
EVOLVE Short DAPT Trial⁵

Excellent Results In
COMPLEX PATIENTS

Lowest ST rate in statistically
more complex patients
Real-World SCAAR Registry⁶

§ EVOLVE Short DAPT is a prospective, multicenter, single-arm trial defining the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with the SYNERGY BP Stent. Approximately 74% of patients enrolled discontinued DAPT at 3-months. N = 1,397 (patients with respective event or sufficient follow-up). Co-primary endpoints: ARC Def/Prob ST and Death/ MI from 3 -15 months.

3. Sarno, G., et al. *Cathet. Cardiovasc. Intervent.* doi:10.1002/ccd.27030.


4. Kang S, et al. *J Am Coll Cardiol. Interv.* doi:10.1016/j.jcin.2016.03.038.

5. EVOLVE Short DAPT Trial presented by Ajay Kirtane, MD, at TCT 2019.

6. Noad RL, Hanratty CG, Walsh SJ. Initial experience of bioabsorbable polymer everolimus-eluting SYNERGY stents in high-risk patients undergoing complex percutaneous coronary intervention with early discontinuation of dual antiplatelet therapy. *J Invasive Cardiol.* Epub December 2016.

SYNERGY™ XD

Everolimus-Eluting Platinum Chromium Coronary Stent System



**Boston
Scientific**
Advancing science for life™

*Dependent on diameter and length.

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
IC-855102-AB.

bostonscientific.com.eu
© 2022 Boston Scientific Corporation or its affiliates. All rights reserved.
C€ 0344